Association Between Use of Antihyperlipidemic Agents and Chronic Obstructive Pulmonary Disease in Patients with Hyperlipidemia: A Population-Based Retrospective Cohort Study

References

• Taiwan COPD Management Guideline. Taiwan Society of Pulmonary and Critical Care Medicine/Health Promotion Administration, Ministry of Health and Welfare; 2019.
   Google Scholar
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 report. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf Accessed 131, 2020.
   Google Scholar
• van ManenJG, BindelsPJ, DekkerFW, et al. The influence of COPD on health-related quality of life independent of the influence of comorbidity. J Clin Epidemiol. 2003;56:1177–1184. doi:10.1016/S0895-4356(03)00208-714680668
   PubMed Web of Science ®Google Scholar
• TerzanoC, ContiV, Di StefanoF, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung. 2010;188(4):321–329. doi:10.1007/s00408-009-9222-y20066539
   PubMed Web of Science ®Google Scholar
• SinDD, AnthonisenNR, SorianoJB, AgustiAG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28:1245–1257. doi:10.1183/09031936.0013380517138679
   PubMed Web of Science ®Google Scholar
• LiaoJK, LaufsU. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118. doi:10.1146/annurev.pharmtox.45.120403.09574815822172
   PubMed Web of Science ®Google Scholar
• McFarlaneS, MuniyappaR, FranciscoR, SowersJ. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002;87(4):1451–1458. doi:10.1210/jcem.87.4.841211932263
   PubMed Web of Science ®Google Scholar
• BelvisiMG, HeleDJ. Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest. 2008;134:152–157.18628217
   PubMed Web of Science ®Google Scholar
• BeckerJ, Delayre‐OrthezC, FrossardN, PonsF. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol. 2006;20:429–447. doi:10.1111/j.1472-8206.2006.00425.x16968414
   PubMed Web of Science ®Google Scholar
• HuangCC, ChanWL, ChenYC, et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. Clin Ther. 2011;33:1365–1370. doi:10.1016/j.clinthera.2011.08.01021962452
   PubMed Web of Science ®Google Scholar
• LiW-F, HuangY-Q, HuangC, FengY-Q. Statins reduce all-cause mortality in chronic obstructive pulmonary disease: an updated systematic review and meta-analysis of observational studies. Oncotarget. 2017;8:73000.29069843
   PubMedGoogle Scholar
• CrinerGJ, ConnettJE, AaronSD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370:2201–2210. doi:10.1056/NEJMoa140308624836125
   PubMed Web of Science ®Google Scholar
• NeukammA, HøisethAD, EinvikG, et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. J Intern Med. 2015;278:59–67. doi:10.1111/joim.1233725495178
   PubMed Web of Science ®Google Scholar
• StolzD, Christ-CrainM, MorgenthalerNG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131:1058–1067. doi:10.1378/chest.06-233617426210
   PubMed Web of Science ®Google Scholar
• GanWQ, ManSF, SenthilselvanA, SinDD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574–580. doi:10.1136/thx.2003.01958815223864
   PubMed Web of Science ®Google Scholar
• DaneshJ, WheelerJG, HirschfieldGM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397. doi:10.1056/NEJMoa03280415070788
   PubMed Web of Science ®Google Scholar
• SidneyS, SorelM, QuesenberryCP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: kaiser permanente medical care program. Chest. 2005;128:2068–2075. doi:10.1378/chest.128.4.206816236856
   PubMed Web of Science ®Google Scholar
• CurkendallSM, DeLuiseC, JonesJK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70. doi:10.1016/j.annepidem.2005.04.00816039877
   PubMed Web of Science ®Google Scholar
• CurkendallSM, LanesS, de LuiseC, et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol. 2006;21:803–813. doi:10.1007/s10654-006-9066-117106760
   PubMed Web of Science ®Google Scholar
• AkhabueE, ThiboutotJ, ChengJW, et al. New and emerging risk factors for coronary heart disease. Am J Med Sci. 2014;347(2):151–158. doi:10.1097/MAJ.0b013e31828aab4523644407
   PubMed Web of Science ®Google Scholar
• RitabrataM, SubinayD, MrinalP, et al. Lipid profile status in chronic obstructive pulmonary disease and association with interleukin 8. Br J Med Med Res. 2015;9.
   Google Scholar
• Zafirova-IvanovskaB, StojkovikjJ, DokikjD, et al. The level of cholesterol in COPD patients with severe and very severe stage of the disease. Maced J Med Sci. 2016;4:277. doi:10.3889/oamjms.2016.063
   Google Scholar
• JainB, PasariN, SongraA, BajpaiA. The lipid profile parameter in chronic obstructive pulmonary disease patients and correlation with severity of disease. J Cardio Thor Med. 2017;5:564–568.
   Google Scholar
• AgustíA, EdwardsLD, RennardSI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7:e37483. doi:10.1371/journal.pone.003748322624038
   PubMed Web of Science ®Google Scholar
• GrundySM, StoneNJ, BaileyAL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:24. doi:10.1016/j.jacc.2018.11.003
   Web of Science ®Google Scholar
• AlexeeffSE, LitonjuaAA, SparrowD, VokonasPS, SchwartzJ. Statin use reduces decline in lung function: VA normative aging study. Am J Respir Crit Care Med. 2007;176:742–747. doi:10.1164/rccm.200705-656OC17673694
   PubMed Web of Science ®Google Scholar
• BlamounA, BattyG, DeBariV, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008;62:1373–1378. doi:10.1111/j.1742-1241.2008.01731.x18422598
   PubMed Web of Science ®Google Scholar
• FrostFJ, PetersenH, TollestrupK, SkipperB. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131:1006–1012. doi:10.1378/chest.06-199717426203
   PubMed Web of Science ®Google Scholar
• KeddissiJI, YounisWG, ChbeirEA, et al. The use of statins and lung function in current and former smokers. Chest. 2007;132:1764–1771. doi:10.1378/chest.07-029817908708
   PubMed Web of Science ®Google Scholar
• LiW-F, HuangY-Q, HuangC, FengY-Q. Statins reduce all-cause mortality in chronic obstructive pulmonary disease: an updated systematic review and meta-analysis of observational studies. Oncotarget. 2017;8(42):73000. doi:10.18632/oncotarget.2030429069843
   PubMedGoogle Scholar
• RaymakersAJ, SadatsafaviM, SinDD, De VeraMA, LyndLD. The impact of statin drug use on all-cause mortality in patients with COPD: a population-based cohort study. Chest. 2017;152:486–493. doi:10.1016/j.chest.2017.02.00228202342
   PubMed Web of Science ®Google Scholar
• ZhangW, ZhangY, LiC-W, et al. Effect of statins on COPD: a meta-analysis of randomized controlled trials. Chest. 2017;152:1159–1168. doi:10.1016/j.chest.2017.08.01528847550
   PubMed Web of Science ®Google Scholar
• WangMT, LoYW, TsaiCL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med. 2013;126(7):598–606. doi:10.1016/j.amjmed.2013.01.03623684060
   PubMed Web of Science ®Google Scholar
• PackardCJ. Management of hypertriglyceridemia: fibrate clinical overview. Eur Heart J. 1998;19(supplA):A62–A65.9519345
   PubMed Web of Science ®Google Scholar
• BelvisiMG, HeleDJ. Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest. 2008;134:52–57.
   Web of Science ®Google Scholar
• DrostEM, PolandCA, DonaldsonK, MacNeeW. Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease. Eur Respir Rev. 2006;15:211–212. doi:10.1183/09059180.00010124
   Google Scholar